DFCI-22-702
Phase II
OPEN TO ACCRUAL
A Phase 2 Study of Epcoritamab and Rituximab for First-Line Treatment of Follicular Lymphoma
SWOG-S2308
Phase III
OPEN TO ACCRUAL
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma